Research programme: haemophilia cell therapy - Living Cell Technologies

Drug Profile

Research programme: haemophilia cell therapy - Living Cell Technologies

Alternative Names: Fac8Cell

Latest Information Update: 01 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Living Cell Technologies
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia

Most Recent Events

  • 01 Mar 2011 No development reported - Preclinical for Haemophilia in USA (Implant)
  • 22 Aug 2007 Preclinical development is ongoing
  • 12 Oct 2005 Preclinical trials in Haemophilia in USA (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top